Cyproheptadine exhibits antitumor activity in urothelial carcinoma cells by targeting GSK3β to suppress mTOR and β-catenin signaling pathways. [electronic resource]
Producer: 20160427Description: 56-65 p. digitalISSN:- 1872-7980
- Angiopoietin-Like Protein 4
- Angiopoietins -- genetics
- Animals
- Antineoplastic Agents -- pharmacology
- Apoptosis -- drug effects
- Cell Line, Tumor
- Cyproheptadine -- pharmacology
- G1 Phase Cell Cycle Checkpoints -- drug effects
- Glycogen Synthase Kinase 3 -- antagonists & inhibitors
- Glycogen Synthase Kinase 3 beta
- Humans
- Mice
- Mice, Inbred BALB C
- Receptors, Serotonin -- analysis
- Signal Transduction -- drug effects
- TOR Serine-Threonine Kinases -- antagonists & inhibitors
- Tuberous Sclerosis Complex 2 Protein
- Tumor Suppressor Proteins -- physiology
- Urinary Bladder Neoplasms -- drug therapy
- beta Catenin -- antagonists & inhibitors
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.